Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TELO with free AI briefings, catalyst countdowns, and dilution alerts.

TELO · Telomir Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.5M Cash on Hand
16.9mo Cash Runway
Follow TELO by email Get an email when TELO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TELO, unsubscribe in one click. Privacy

📣 What TELO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Zn-Telomir Triple-Negative Breast Cancer (TNBC) Phase 1/2 · NCT07581314 Not yet recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TELO holds $4.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $799,386/quarter from operations, an estimated runway of 16.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 68 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TELO files for a raise →

👥 Who Owns TELO

Insiders 21.5% Other 5%+ holders 4.8% Institutions (33 holders) 4.1% Public and other holders 69.6%
HolderTypeShares% of sharesAs of
Erez Aminov
CEO and Chairman, Director · +6.36M options
Insider 7,319,710 9.94% 2026-05-21
John Paul DeJoria, as trustee of the Joh 5%+ holder (13G) 3,554,871 4.83% 2026-06-30
MIRA PHARMACEUTICALS, INC.
10% owner
Insider 3,521,127 4.78% 2025-09-29
Bay Shore Trust
10% owner · +2.34M options
Insider 3,292,696 4.47% 2024-02-13
Christopher C JR Chapman
CEO & Chairman, Director
Insider 975,610 1.32% 2024-02-08
Craig Eagle
Director
Insider 487,805 0.66% 2024-02-08
Nathen Fuentes
Chief Financial Officer
Insider 101,134 0.14% 2024-02-08
Talhia Tuck
Director
Insider 48,781 0.07% 2024-02-08
Bradley Kroenig
Director
Insider 48,781 0.07% 2024-02-08
Hugh III McColl
Director
Insider 48,781 0.07% 2024-02-08
Michelle Yanez
Chief Financial Officer · +200,000 options
Insider 24,391 0.03% 2024-06-18

Share count 73,675,706 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TELO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TELO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.